Hutch News
Breaking down HIV exclusions in cancer clinical trials
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life
On immunotherapy trial, long-term survivors of deadly skin cancer point to a hopeful future
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma
Seattle team pivotal to FDA OK on drug for rare skin cancer
UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer
Meet Global Oncology's deputy program head
Key early experiences shaped Dr. Thomas Uldrick's path toward HIV-associated cancers, global health
Science to watch in 2018: From immunotherapy to gene therapy, big data to new tech
Fred Hutch experts lend their predictions for the coming year’s advances
Dr. Carl June weaves together HIV and cancer research to advance cures for both
CAR T-cell pioneer and one-time bone marrow transplant fellow will give keynote at HIV cure conference
Good News: Gene therapy for sickle cell disease, and more
Celebrating faculty and staff achievements
Inaugural 'Oncology Summit' addresses academic-industry partnerships
Fred Hutch, Merck co-host inaugural ‘Oncology Summit’ to capture non-profit and for-profit outlooks on cancer care
'Finally showing hope': Immunotherapy trial results transforming care for rare skin cancer
Immunotherapy trial results transforming care for rare skin cancer
6 questions in cancer immunotherapy
From cancer vaccines to engineered T cells, experts weigh in on the big unknowns
Scratching the surface of a rare skin cancer
Immune-boosting therapy shows promise for advanced Merkel cell carcinoma
What Uganda is teaching us about cancer
<p>Fred Hutch-Uganda alliance builds a new cancer center on the shoulders of giants</p>
Cancer Immunotherapy Trials Network selects member sites
Center-based initiative announces 27 institutional partners in national research effort to accelerate clinical trials of promising cancer immunotherapies
Fred Hutchinson Cancer Research Center to lead immunotherapy clinical trials network
More than two dozen research institutes in the U.S. and Canada to participate
Center awarded $11.5 million for breast cancer research consortium
Porter, Cheever will lead the five-year Seattle-based SPORE in projects including development of targeted treatments for drug-resistant tumors
NCI awards $11.5 million to Fred Hutchinson Cancer Research Center to lead breast cancer research consortium
Projects include developing targeted therapies to treat drug-resistant tumors
Immunologists’ ‘team science’ honored
Collaborative achievements in T-cell immunotherapies cited
$17 million award launches Cancer Immunotherapy Trials Network
Center to lead national, multi-institutional clinical trials effort
'We're ready to take off'
Mac Cheever pilots program poised to lead the nation in translational research for breast, prostate, colorectal and other solid-tumor cancers
Partnership for success
Emerging research programs, pediatric oncology, solid-tumor research areas are the focus of the Cancer Consortium's annual external review